Keywords
How to Cite
Abstract
Introduction:
Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma worldwide. This disease is especially important in Latin America due to the high prevalence in the region (1) (2). In patients with high risk, treatment results have been disappointing.
Objective:
Evaluate of progression-free survival in patients with high-risk DLBCL by IPI (International Prognostic Index) treated at the Clínica Universitaria Colombia between the years 2012 - 2019 who received EPOCHR or R-CHOP as first line therapy.
Materials and methods:
A retrospective cohort-type analytical study was conducted. Patients with diagnosis of high-risk DLBCL who received chemotherapy with RCHOP or EPOCH R were selected. Progression-free survival was assessed as the main outcome. The data were evaluated by means of Kaplan Meier curves and compared by means of log Rank test, a multivariate analysis was carried out through a Cox model.
Results:
The median progression-free survival in the RCHOP group was 61.7 months (95% CI 15.2 - NA), while in the group that received the EPOCH R it had not been reached at the time of follow-up. The probability of progression-free survival at 2 years was 66% (95% CI 44.4% to 98.2%) and 63% (95% CI 50.6% to 78.4%) for EPOCHR and RCHOP, respectively (p = 0.7), no differences in overall survival were found-
Conclusion:
No differences were found in terms of progression-free survival between the two treatments.
References
2. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA C. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute [Internet]. 2019. Disponible en: https://seer.cancer.gov/csr/1975_2016/
3. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Muller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 1 de octubre de 2016;101(10):1244-50.
4. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes: 2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes. CA Cancer J Clin. 12 de noviembre de 2016;66(6):443-59.
5. Combariza JF, Lombana M, Torres AM, Castellanos AM, Arango M. General features and epidemiology of lymphoma in Colombia. A multicentric study. Ann Hematol. junio de 2015;94(6):975-80.
6. Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. mayo de 2006;7(5):379-91.
7. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. febrero de 2008;9(2):105-16.
8. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20 + B-Cell Lymphoma in the Rituximab Era. J Clin Oncol. 10 de mayo de 2010;28(14):2373-80.
9. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 15 de abril de 2002;99(8):2685-93.
10. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. J Clin Oncol. 1 de junio de 2008;26(16):2717-24.
11. Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol. abril de 2015;169(2):188-98.
12. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 9 de octubre de 2014;124(15):2354-61.
13. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 10 de julio de 2017;35(20):2260-7.
14. Wilson WH, Jung S-H, Porcu P, Hurd D, Johnson J, Martin SE, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 1 de mayo de 2012;97(5):758-65.
15. Bartlett NL, Wilson WH, Jung S-H, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 20 de julio de 2019;37(21):1790-9.
16. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 24 de noviembre de 2016;128(21):2489-96.
17. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 20 de septiembre de 2014;32(27):3059-67.
18. Šimkovič M, Móciková H, Ďuraš J, Kamarádová K, Štěpánková P, Janíková A, et al. DA-EPOCH-R VERSUS R-CHOP IN HIGH RISK DLBCL PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP (CLSG). Hematol Oncol. junio de 2019;37:433-4.
19. Zhang X-Y, Liang J-H, Wang L, Zhu H-Y, Wu W, Cao L, et al. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma. J Cancer Res Clin Oncol. enero de 2019;145(1):117-27.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar